Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization
- 239 Downloads
To determine the association between device-determined diagnostic indices, including intrathoracic impedance, and heart failure (HF) hospitalization.
Clinical and device diagnostic data of 558 HF patients indicated for CRT-D therapy (In Sync Sentry, Medtronic Inc.) were prospectively collected from 34 centers. Device-recorded intrathoracic impedance fluid index threshold crossing event (TCE), mean activity counts, tachyarrhythmia events, night heart rate (NHR) and heart rate variability (HRV) were compared within patients with vs. without documented HF hospitalization.
Mean follow-up was 326 ± 216 days. Patients hospitalized for HF had significantly higher rates of TCE, a higher percentage of days with the thoracic impedance fluid index above the programmed threshold, a higher percentage of days with low activity, with low HRV or with high NHR.
Multivariate analysis showed that TCE resulted in a 36% increased probability of HF hospitalization. Both TCE duration and patient activity were also significantly associated with hospitalization. Kaplan Meier analysis indicated that patients with more TCE events were significantly more likely to be hospitalized (log rank test, p = 0.005).
Decreased intrathoracic impedance, low patient activity and low HRV were all independently associated with increased risk for HF hospitalization in HF patients treated with resynchronization therapy. Device-derived diagnostic data may provide valuable and reliable indices for the prognostic stratification of HF patients.
KeywordsImpedance Arrhythmias Heart rate variability Heart rate Activity Cardiac resynchronization therapy Heart failure
The authors would like to thank Clinical Service Team of Medtronic Italy for the Clinical Service project organization and management.
Annamaria Varbaro, Alessandra Denaro, S. Sarkar, D.A. Hettrick are employees of Medtronic, Inc.
Conflict of interest statement
No other conflict of interest exists.
- 1.Adamson, P. B., Smith, A. L., Abraham, W. T., Kleckner, K. J., Stadler, R. W., Shih, A., et al. (2004). Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation, 110(16), 2389–2394.PubMedCrossRefGoogle Scholar
- 2.Vollmann, D., Nagele, H., Schauerte, P., Wiegand, U., Butter, C., Zanotto, G., et al. (2007). Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. European Heart Journal, 28(15), 1835–1840.PubMedCrossRefGoogle Scholar
- 6.Maines, M., Catanzariti, D., Cemin, C., Vaccarini, C., & Vergara, G. (2007). Usefulness of intrathoracic fluids accumulation monitoring with an implantable biventricular defibrillator in reducing hospitalizations in patients with heart failure: A case-control study. Journal of Interventional Cardiac Electrophysiology, 19(3), 201–207.PubMedCrossRefGoogle Scholar
- 9.Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Brown, M. W., Andrews, M. L., & Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346(12), 877–883.PubMedCrossRefGoogle Scholar
- 10.Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225–237.PubMedCrossRefGoogle Scholar